Health Care [ 9/12 ] | Biotechnology [ 47/73 ]
NASDAQ | Common Stock
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines.
Its lead clinical-stage program includes ORX750, an orally administered OX2R agonist in a Phase 2a study for the treatment of idiopathic hypersomnia and narcolepsy type 1 and 2.
The company also develops ORX142 for the treatment of neurological and neurodegenerative disorders, as well as other potential symptoms, including excessive daytime sleepiness, impaired attention, cognitive deficits, and fatigue; and ORX489 for the treatment of neuropsychiatric disorders.
In addition, it offers LockBody, which is designed to selectively drive potent effector function activity, such as CD3, into the tumor microenvironment.
Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 14, 25 | -0.20 Increased by +47.37% | -0.28 Increased by +28.57% |
| Mar 24, 25 | -0.58 Decreased by -53.92% | -0.35 Decreased by -64.76% |
| Nov 12, 24 | -0.37 Increased by +7.50% | -0.39 Increased by +4.52% |
| Aug 13, 24 | -0.40 Decreased by -53.85% | -0.40 Decreased by -0.83% |
| May 13, 24 | -0.38 Increased by +28.30% | -0.42 Increased by +9.52% |
| Mar 28, 24 | -0.38 Increased by +15.56% | -0.48 Increased by +20.83% |
| Nov 13, 23 | -0.40 Increased by +29.82% | -0.52 Increased by +23.08% |
| Aug 14, 23 | -0.26 Increased by +62.32% | -0.49 Increased by +46.94% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 25 | 15.00 M Increased by +N/A% | -26.14 M Increased by +31.27% | Decreased by -174.23% Decreased by N/A% |
| Dec 31, 24 | 0.00 Decreased by -100.00% | -111.33 M Decreased by -199.61% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 24 | 0.00 Decreased by N/A% | -42.57 M Decreased by -10.14% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by N/A% | -43.82 M Decreased by -76.07% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by N/A% | -38.02 M Increased by +25.02% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 6.91 M Increased by +N/A% | -37.16 M Increased by +13.93% | Decreased by -537.53% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -38.65 M Increased by +28.26% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -24.89 M Increased by +61.51% | Decreased by N/A% Decreased by N/A% |